Revolution Medicines’ daraxonrasib (RMC-6236) produced objective response rates near 47% in a first-line cohort of RAS-mutant metastatic pancreatic ductal adenocarcinoma (PDAC), according to company-reported data. The multi-selective RAS(ON) tri-complex inhibitor showed disease control rates above historic chemotherapy benchmarks and a more favorable Grade ≥3 adverse event profile compared with standard regimens. Investigators and the company are positioning daraxonrasib to advance into Phase 3 (RASolute 303), arguing the oral RAS-targeted approach could offer a chemotherapy-sparing alternative for >90% of PDAC cases driven by KRAS mutations. Progression-free and overall survival data remain immature; sponsors will need confirmatory randomized data to displace entrenched chemotherapy standards.